West Pharmaceutical Services reported second-quarter revenue of $872 million, up 13% organically, and adjusted earnings per share of $2.37, a 29% increase year-over-year. The company raised its full-year 2026 guidance, now expecting organic revenue growth of 10% to 11% and adjusted EPS between $8.85 and $9.05. Proprietary Products segment organic growth reached 16%, led by a 29% organic increase in the Biologics market group, while high-value product components revenue rose 18% organically to $424 million, now representing 49% of total company revenues. Gross margin improved 200 basis points to 37.7%, and adjusted operating margin expanded 230 basis points to 22.6%. The company repurchased 0.5 million shares for $157 million during the quarter and reported operating cash flow of $124 million against capital expenditures of $43 million.
West Pharmaceutical Services IncStrong Q2 earnings beat and raised 2026 guidance